View Older Stories
-
Daiichi Sankyo gets US approval for Datroway in metastatic breast cancer
-
AstraZeneca's camizestrant wins EU panel backing for breast cancer
-
Trump to unveil more discounted prescription drug options - CNBC
-
AstraZeneca's BAXFENDY wins FDA approval for resistant hypertension
-
AstraZeneca receives FDA approval for hypertension drug Baxfendy
-
AstraZeneca drug combo shows survival benefit in bladder cancer trial
-
AstraZeneca drug meets primary endpoint in rare disease trial
-
Health officials explore restrictions on certain SSRI antidepressants - Reuters
-
FDA Advisory Committee recommends TRUQAP for prostate cancer subtype
-
FDA Panel Votes 6-3 'no' On Astrazeneca Breast Cancer Drug
-
AstraZeneca (AZN) Tops Q1 EPS by 6c; offers guidance
-
AstraZeneca Q1 preview: In-line quarter expected as pipeline catalysts take center stage
-
AstraZeneca, Amgen partner with FDA to test real-time AI trial monitoring
-
AstraZeneca's BREZTRI wins US approval for asthma treatment
-
AstraZeneca wins FDA approval for SAPHNELO autoinjector pen for lupus
-
AstraZeneca's tozorakimab meets primary endpoint in Phase III COPD trial
-
AstraZeneca reports positive Phase III trial results for COPD drug
-
AstraZeneca (AZN) PT Raised to $220 at Morgan Stanley
-
AstraZeneca (AZN:LN) (AZN) PT Raised to GBp16,500 at Morgan Stanley
-
FDA approves multiple generics of Farxiga
-
AstraZeneca's IMFINZI and IMJUDO combination shows progression benefit in liver cancer
-
AstraZeneca (AZN) call put ratio 1.2 calls to 1 put as share price up 5%
-
AstraZeneca (AZN) 6K contracts of April 220 calls trade
-
AstraZeneca reports mixed results for HPP drug efzimfotase alfa
-
TD Cowen Reiterates Buy Rating on AstraZeneca (AZN) Amid Potential 'Multi-Billion $ Opportunity'
-
AstraZeneca (AZN) PT Raised to $220 at Leerink Partners
-
AstraZeneca drug meets goals in two COPD trials
-
Advancements in Novel Immunotherapeutics in The Oncology Battle
-
These are the best EU pharma stocks to buy: analyst
-
TD Cowen: 'AstraZeneca's (AZN) history of innovation offers opportunity for upside'
-
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP160 at Guggenheim
-
ENHERTU receives priority review for HER2-positive early breast cancer
-
AstraZeneca (AZN) PT Raised to $219 at Morgan Stanley
-
AstraZeneca (AZN) PT Raised to $109 at Morgan Stanley
-
AstraZeneca's CALQUENCE plus venetoclax wins FDA approval for CLL treatment
-
EMA validates ENHERTU application for early breast cancer treatment
-
This global pharma stock is ‘still underappreciated’, Bernstein says
-
AstraZeneca BREZTRI shows lung function improvements in asthma trials
-
AstraZeneca awards $3.4 million to nonprofits for health equity programs
-
AstraZeneca (AZN) Reports Q4 EPS of $2.12; offers guidance
-
AstraZeneca forecasts 2026 sales, profit growth as Q4 meets expectations; stock up
-
AstraZeneca is set to report on Tuesday. Here's what to watch out for.
-
FDA grants Priority Review to DATROWAY for metastatic triple-negative breast cancer
-
FDA grants Priority Review to DATROWAY for metastatic breast cancer
-
AstraZeneca starts trading on NYSE under harmonized global structure
-
AstraZeneca partners with CSPC on weight management drugs for $1.2B
-
AstraZeneca plans $15 billion China investment through 2030
-
Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'
-
AstraZeneca to move listing from NASDAQ to NYSE in January
-
Guggenheim Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)

